IntroductionSickle cell disease (SCD) is a common and severe disorder in which a missense mutation in the -globin gene results in polymerization of hemoglobin S under deoxygenating conditions, leading to chronic peripheral hemolysis and intravascular vaso-occlusion. Less fully appreciated is the extent to which sickle hemoglobin in committed erythroid precursor cells might also affect earlier events in erythropoiesis. Improved understanding of the impact of SCD on intramedullary erythropoiesis is relevant to the development of new therapeutic strategies for this chronic debilitating disease.One approach to directly assess the contribution of ineffective erythropoiesis to the pathophysiology of sickle cell disease is to analyze erythropoiesis in sickle cell disease patients who have undergone matched related donor allogeneic stem cell transplantation (SCT) following a nonmyeloablative (NMA) conditioning regimen. A variety of nonmyeloablative conditioning regimens have been developed to facilitate engraftment of donor stem cells and reduce the treatment-related toxicity of hematopoietic SCT. [1][2][3][4] In this nonmyeloablative setting, host hematopoiesis frequently persists following transplantation and coexists with engrafted donor cells within the marrow. Depending on the underlying disease and the intensity of the conditioning regimen, stable mixed hematopoietic chimerism occurs frequently and can persist for long intervals. Mixed hematopoietic chimerism has been well documented after allogeneic hematopoietic SCT for SCD, and this provides a unique opportunity to perform a direct side-by-side comparison of normal and sickle erythropoiesis in vivo. 5,6 To distinguish between donor and host erythropoiesis, we previously developed methods to specifically measure erythroid lineage chimerism in both nucleated and non-nucleated erythroid elements. Although molecular methods for measurement of donor chimerism are well established, they are based on analysis of genomic DNA, and thus measure nucleated-cell chimerism, which is predominantly leukocyte derived in peripheral blood. 7-9 Therefore, in addition to measuring overall engraftment by analysis of genomic DNA, the present studies also use two alternate methods to distinguish between donor and host-derived erythropoiesis. One method relies on direct enumeration of donor-derived erythroid precursors on paraffin-imbedded marrow sections following staining with a donor-specific marker, such as red blood cell (RBC) isohemagglutinin antigens in an ABO disparate setting. A second method uses a novel molecular assay, RNA -globin pyrosequencing, which directly measures erythroid lineage-specific chimerism from total RNA by quantifying the amount of RBC-specific RNA transcripts that bear a donor or host-specific single nucleotide polymorphism (SNP) or mutation. 6 In addition to using the sickle mutation as an informative -globin SNP, we also previously identified an alternate -globin SNP, 3H3, that occurs at high minor allele frequency. 6 Since -globin RNA is expressed...